14.67
Arcutis Biotherapeutics Inc stock is traded at $14.67, with a volume of 1.69M.
It is down -5.23% in the last 24 hours and up +7.32% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$15.48
Open:
$15.65
24h Volume:
1.69M
Relative Volume:
0.90
Market Cap:
$1.75B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-3.7423
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-2.27%
1M Performance:
+7.32%
6M Performance:
+15.69%
1Y Performance:
+50.15%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ARQT
Arcutis Biotherapeutics Inc
|
14.67 | 1.79B | 59.61M | -262.14M | -247.49M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-30-24 | Initiated | H.C. Wainwright | Buy |
Aug-28-24 | Initiated | Jefferies | Buy |
Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
Sep-07-22 | Initiated | Needham | Buy |
Mar-17-22 | Initiated | Goldman | Buy |
Jun-30-21 | Initiated | Mizuho | Buy |
May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
Oct-08-20 | Initiated | Truist | Buy |
Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
Feb-25-20 | Initiated | Cowen | Outperform |
Feb-25-20 | Initiated | Goldman | Neutral |
Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
What analysts say about Arcutis Biotherapeutics Inc. stockExplosive portfolio gains - Jammu Links News
What drives Arcutis Biotherapeutics Inc. stock priceHigh-impact stock picks - Jammu Links News
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
Is Arcutis Biotherapeutics Inc. a good long term investmentTriple-digit wealth increases - Jammu Links News
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st
Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
FDA News and Decisions: Midyear Updates - Dermatology Times
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN
Arcutis Biotherapeutics - WBFF
Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria
Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan
Mercedes Gonzalez, MD, discusses phase 2 trial of roflumilast cream 0.05% for infant atopic dermatitis - Contemporary Pediatrics
Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus
ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan
Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges - Investing.com Australia
Arcutis Biotherapeutics (ARQT) Begins Trial for Infant Atopic De - GuruFocus
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - Taiwan News
Breakthrough: New Eczema Treatment Trial Launches for 3-Month-Old Infants, Targeting 9.6M Children - Stock Titan
Arcutis says Zoryve data demonstrates durable atopic dermatitis improvements - MSN
H.C. Wainwright maintains $19 target on Arcutis stock - Investing.com Australia
H.C. Wainwright maintains $19 target on Arcutis stock By Investing.com - Investing.com South Africa
Wellington Management Group LLP Sells 3,882 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq L - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ARQT Stock News - GuruFocus
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Arcutis Grants 72,000 Restricted Stock Units to 9 New Hires: Key Details on 4-Year Vesting Plan - Stock Titan
Arcutis Presents Long-Term INTEGUMENT-OLE Data on Roflumilast at RAD 2025 - Dermatology Times
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Benzinga
Road to RAD: What to Expect - Dermatology Times
ARQT Reveals Promising Long-Term Data for Zoryve in Atopic Derma - GuruFocus
Arcutis Biotherapeutics director Heron buys $30,246 in stock By Investing.com - Investing.com India
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):